{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:48:30Z","timestamp":1792032510237,"version":"4.4.0"},"reference-count":104,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2006,8,31]],"date-time":"2006-08-31T00:00:00Z","timestamp":1156982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the absence of curative options, therapy for aggressive forms of systemic mastocytosis (SM) has relied in the use of cytoreductive agents, mainly interferon\u2010\u03b1 (IFN\u2010\u03b1) and cladribine. However, responses are transient and only occur in a subset of patients. Gain\u2010of\u2010function mutations at codon 816 of the KIT protooncogene lead to constitutively active Kit receptor molecules, which are central to the pathogenesis of SM. Recent advances in the understanding of the molecular underpinnings of SM have led to the development of small molecules targeting mutant Kit tyrosine kinase isoforms that significantly have widened the range of therapeutic options for patients with SM. Some of these promising agents, such as dasatinib, AMN107, and PKC412, currently are under investigation in clinical trials whereas, others are at different stages of preclinical development. In addition, monoclonal antibodies directed to neoplastic mast cell\u2010restricted surface antigens constitute a viable option for the treatment of SM that warrants further investigation. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.22187","type":"journal-article","created":{"date-parts":[[2006,8,31]],"date-time":"2006-08-31T16:50:43Z","timestamp":1157043043000},"page":"1429-1439","source":"Crossref","is-referenced-by-count":43,"title":["Novel approaches in the treatment of systemic mastocytosis"],"prefix":"10.1002","volume":"107","author":[{"given":"Alfonso","family":"Quintas\u2010Cardama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,9,18]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400010775"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000085561"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116761"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114865"},{"key":"e_1_2_10_6_2","first-page":"291","volume-title":"World Health Organization (WHO) Classification of Tumors. Pathology and Genetics. Tumors of Hematopoietic and Lymphoid Tissues","author":"Valent P","year":"2001"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.9.2237.2237"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009058500"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00041-3"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0006"},{"key":"e_1_2_10_11_2","first-page":"871","article-title":"FIP1L1\u2010PDGFRA and c\u2010kit D816V mutation\u2010based clonality studies in systemic mast cell disease associated with eosinophilia","volume":"89","author":"Tefferi A","year":"2004","journal-title":"Haematologica."},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0787"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.014860"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00038-8"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00168-6"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pai.0000173054.83414.22"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2004-0117"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C300186200"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.23.10560"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02783.x"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0396-312"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(99)00145-9"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00093-6"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2120::AID-CNCR10>3.0.CO;2-C"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1627"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(99)00256-3"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)70243-9"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.880"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1824"},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0932698100"},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202273260912"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70301-4"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04575.x"},{"key":"e_1_2_10_34_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.55.091902.103822"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200401000-00009"},{"key":"e_1_2_10_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000085560"},{"key":"e_1_2_10_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00185-1"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(03)00112-7"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2042.x"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200012)65:4<307::AID-AJH10>3.0.CO;2-F"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.4.1609"},{"key":"e_1_2_10_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3816"},{"key":"e_1_2_10_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2003.015156"},{"key":"e_1_2_10_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00414.x"},{"key":"e_1_2_10_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D"},{"key":"e_1_2_10_46_2","first-page":"100","article-title":"Inhibition of the Abl protein\u2010tyrosine kinase in vitro and in vivo by a 2\u2010phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger E","year":"1996","journal-title":"Cancer Res."},{"key":"e_1_2_10_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_10_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020150"},{"key":"e_1_2_10_49_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein\u2010tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c\u2010kit and platelet\u2010derived growth factor receptors","volume":"295","author":"Buchdunger E","year":"2000","journal-title":"J Pharmacol Exp Ther."},{"key":"e_1_2_10_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.925"},{"key":"e_1_2_10_51_2","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild\u2010type c\u2010Kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost M","year":"2002","journal-title":"Mol Cancer Ther."},{"key":"e_1_2_10_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1741"},{"key":"e_1_2_10_53_2","doi-asserted-by":"publisher","DOI":"10.4065\/77.11.1169"},{"key":"e_1_2_10_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00065-1"},{"key":"e_1_2_10_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025217"},{"key":"e_1_2_10_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14115-3"},{"key":"e_1_2_10_57_2","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood.V104.11.1516.1516","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis, a Phase I\/II trial","volume":"104","author":"Droogendijk H","year":"2004","journal-title":"Blood."},{"key":"e_1_2_10_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-3022"},{"key":"e_1_2_10_59_2","first-page":"197","article-title":"Systemic mastocytosis: current concepts and treatment advances","volume":"3","author":"Tefferi A","year":"2004","journal-title":"Curr Hematol Rep."},{"key":"e_1_2_10_60_2","doi-asserted-by":"publisher","DOI":"10.1159\/000048189"},{"key":"e_1_2_10_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2393"},{"key":"e_1_2_10_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"e_1_2_10_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403887"},{"key":"e_1_2_10_64_2","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/blood.V106.11.3528.3528","article-title":"Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild\u2010type or mutated codon 816 c\u2010kit","volume":"106","author":"Verstovsek S","year":"2005","journal-title":"Blood."},{"key":"e_1_2_10_65_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_2_10_66_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_10_67_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2050"},{"key":"e_1_2_10_68_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-3969"},{"key":"e_1_2_10_69_2","first-page":"17","article-title":"PKC412\u2010a protein kinase inhibitor with a broad therapeutic potential","volume":"15","author":"Fabbro D","year":"2000","journal-title":"Anticancer Drug Des."},{"key":"e_1_2_10_70_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1568"},{"key":"e_1_2_10_71_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4617"},{"key":"e_1_2_10_72_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-05-0114"},{"key":"e_1_2_10_73_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2873"},{"key":"e_1_2_10_74_2","doi-asserted-by":"publisher","DOI":"10.1159\/000048179"},{"key":"e_1_2_10_75_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2189"},{"key":"e_1_2_10_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00070-3"},{"key":"e_1_2_10_77_2","first-page":"3127","article-title":"The pyrido[2,3\u2010d]pyrimidine derivative PD180970 inhibits p210 Bcr\u2010Abl tyrosine kinase and induces apoptosis of K562 leukemic cells","volume":"60","author":"Dorsey J","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_10_78_2","first-page":"4244","article-title":"Characterization of potent inhibitors of the Bcr\u2010Abl and the c\u2010kit receptor tyrosine kinases","volume":"62","author":"Wisniewski D","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_10_79_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4771"},{"key":"e_1_2_10_80_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0350"},{"key":"e_1_2_10_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0896(03)00048-8"},{"key":"e_1_2_10_82_2","first-page":"1721","article-title":"Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition","volume":"52","author":"Whitesell L","year":"1992","journal-title":"Cancer Res."},{"key":"e_1_2_10_83_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.18.8324"},{"key":"e_1_2_10_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4914(02)02316-X"},{"key":"e_1_2_10_85_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2477"},{"key":"e_1_2_10_86_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470033449.ch15"},{"key":"e_1_2_10_87_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2648"},{"key":"e_1_2_10_88_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704103361506"},{"key":"e_1_2_10_89_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.16.1.225"},{"key":"e_1_2_10_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(00)00018-6"},{"key":"e_1_2_10_91_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M210849200"},{"key":"e_1_2_10_92_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3247"},{"key":"e_1_2_10_93_2","first-page":"3071","article-title":"The proteasome inhibitor PS\u2010341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima T","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_10_94_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3559"},{"key":"e_1_2_10_95_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2433"},{"key":"e_1_2_10_96_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000138181.89743.7b"},{"key":"e_1_2_10_97_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0960-135X.2004.01369.x"},{"key":"e_1_2_10_98_2","doi-asserted-by":"crossref","first-page":"11885","DOI":"10.1016\/S0021-9258(19)38482-0","article-title":"Structure\/function analysis of interleukin\u20102\u2010toxin (DAB486IL\u20102): fragment B sequences required for the delivery of fragment A to the cytosol of target cells","volume":"265","author":"Williams D","year":"1990","journal-title":"J Biol Chem."},{"key":"e_1_2_10_99_2","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/4.4.463"},{"key":"e_1_2_10_100_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.167.2.612"},{"key":"e_1_2_10_101_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2000.s.005"},{"key":"e_1_2_10_102_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.376"},{"key":"e_1_2_10_103_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U"},{"key":"e_1_2_10_104_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.4.1237"},{"key":"e_1_2_10_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(02)00925-6"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22187","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:54:56Z","timestamp":1760288096000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,18]]},"references-count":104,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1002\/cncr.22187"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22187","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,18]]}}}